mirtazapine has been researched along with DDPAC in 1 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Excerpt | Relevance | Reference |
---|---|---|
"In terms of antidepressant drugs prescribed in hospital admission, during stay and discharge, the number of sertraline and venlafaxine prescriptions were associated with the number of VaD patients whilst the number of mirtazapine prescriptions was associated with frontotemporal dementia patients." | 4.12 | Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitals. ( Finn, DP; Joshi, A; McClean, PL; Todd, S; Wong-Lin, K, 2022) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Joshi, A | 1 |
Todd, S | 1 |
Finn, DP | 1 |
McClean, PL | 1 |
Wong-Lin, K | 1 |
1 other study available for mirtazapine and DDPAC
Article | Year |
---|---|
Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitals.
Topics: Aged; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Depression; Donepezil; Dothiepin | 2022 |